Long-term trends in hepatitis C prevalence, treatment uptake and liver-related events in the Swiss HIV Cohort Study.

Baumann, Lukas; Braun, Dominique L; Cavassini, Matthias; Stoeckle, Marcel; Bernasconi, Enos; Schmid, Patrick; Calmy, Alexandra; Haerry, David; Béguelin, Charles; Fux, Christoph A; Wandeler, Gilles; Surial, Bernard; Rauch, Andri (2024). Long-term trends in hepatitis C prevalence, treatment uptake and liver-related events in the Swiss HIV Cohort Study. Liver international, 44(1), pp. 169-179. Wiley 10.1111/liv.15754

Preview

Text Liver_International_-_2023_-_Baumann_-_Long_term_trends_in_hepatitis_C_prevalence_treatment_uptake_and_liver_related.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC). Download (942kB) | Preview

BACKGROUND AND AIMS

Treatment for chronic hepatitis C virus (HCV) infections changed dramatically in the last decade. We assessed changes in the prevalence of replicating HCV infection, treatment uptake and liver-related morbidity and mortality in persons with HIV (PWH) and hepatitis C in the Swiss HIV cohort study.

METHODS

We included all cohort participants between 2002 and 2021. We assessed yearly prevalence of replicating HCV infection, overall and liver-related mortality, as well as the yearly incidence of liver-related events in persons with at least one documented positive HCV-RNA.

RESULTS

Of 14 652 participants under follow-up, 2294 had at least one positive HCV-RNA measurement. Of those, 1316 (57%) ever received an HCV treatment. Treatment uptake increased from 8.1% in 2002 to a maximum of 32.6% in 2016. Overall, prevalence of replicating HCV infection declined from 16.5% in 2004 to 1.3% in 2021. HCV prevalence declined from 63.2% to 7.1% in persons who inject drugs, and from 4.1% to 0.6% in men who have sex with men. Among the 2294 persons with replicating HCV infection, overall mortality declined from a maximum of 3.3 per 100 patient-years (PY) to 1.1 per 100 PY, and incidence of liver-related events decreased from 1.4/100 PY to 0.2/100 PY.

CONCLUSIONS

The introduction of DAA therapy was associated with a more than 10-fold reduction in prevalence of replicating HCV infection in PWH, approaching the estimates in the general population. Overall mortality and liver-related events declined substantially in persons living with HIV and hepatitis C.

Interest & Impact

Downloads

3 since deposited on 19 Oct 2023
3 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item